Drugs / SGN1
SGN1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05103345 | Apr 2023 → Dec 2027 expected | neoplasm | Guangzhou Sinogen Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05038150 | Jan 2023 → Jan 2028 expected | neoplasm | Guangzhou Sinogen Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05038150 ↗ |
| Known as | Salmet-vec | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315037 ↗ |
| Known as | Salmonella vnp20009 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315037 ↗ |
| Modality | Other / unclassified | “SGN1 is a genetically modified strain of Salmonella enterica, serotype typhimurium” NCT05038150 ↗ |
| Route | Intravenous | “administered as an IV infusion” NCT05038150 ↗ |